Barclays’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.76M | Buy |
58,370
+5,291
| +10% | +$382K | ﹤0.01% | 1875 |
|
|
2026
Q1 | $3.62M | Sell |
53,079
-167,117
| -76% | -$11.8M | ﹤0.01% | 2009 |
|
|
2025
Q4 | $16.7M | Sell |
220,196
-19,453
| -8% | -$1.41M | ﹤0.01% | 1348 |
|
|
2025
Q3 | $14.7M | Sell |
239,649
-40,163
| -14% | -$2.09M | ﹤0.01% | 1399 |
|
|
2025
Q2 | $13.7M | Buy |
279,812
+147,473
| +111% | +$7M | ﹤0.01% | 1356 |
|
|
2025
Q1 | $6.74M | Sell |
132,339
-31,509
| -19% | -$1.57M | ﹤0.01% | 1686 |
|
|
2024
Q4 | $7.4M | Sell |
163,848
-3,164
| -2% | -$135K | ﹤0.01% | 1817 |
|
|
2024
Q3 | $6.2M | Buy |
167,012
+102,138
| +157% | +$3.42M | ﹤0.01% | 1896 |
|
|
2024
Q2 | $1.98M | Sell |
64,874
-28,024
| -30% | -$908K | ﹤0.01% | 2158 |
|
|
2024
Q1 | $2.7M | Sell |
92,898
-160,404
| -63% | -$4.49M | ﹤0.01% | 2319 |
|
|
2023
Q4 | $6.98M | Buy |
253,302
+110,652
| +78% | +$2.53M | ﹤0.01% | 1816 |
|
|
2023
Q3 | $3.2M | Buy |
142,650
+30,435
| +27% | +$1.13M | ﹤0.01% | 1601 |
|
|
2023
Q2 | $4.56M | Buy |
112,215
+27,124
| +32% | +$1.33M | ﹤0.01% | 1406 |
|
|
2023
Q1 | $4.12M | Sell |
85,091
-46,855
| -36% | -$2.14M | ﹤0.01% | 1677 |
|
|
2022
Q4 | $5.04M | Sell |
131,946
-120
| -0.1% | -$4.99K | ﹤0.01% | 1628 |
|
|
2022
Q3 | $6.63M | Buy |
132,066
+108,178
| +453% | +$5.3M | 0.01% | 1021 |
|
|
2022
Q2 | $957K | Sell |
23,888
-30,556
| -56% | -$1.07M | ﹤0.01% | 2397 |
|
|
2022
Q1 | $2.03M | Sell |
54,444
-41,298
| -43% | -$1.59M | ﹤0.01% | 1853 |
|
|
2021
Q4 | $3.81M | Buy |
95,742
+36,302
| +61% | +$1.39M | ﹤0.01% | 1906 |
|
|
2021
Q3 | $2.21M | Buy |
59,440
+43,802
| +280% | +$1.8M | ﹤0.01% | 2260 |
|
|
2021
Q2 | $661K | Sell |
15,638
-70,943
| -82% | -$3.04M | ﹤0.01% | 2908 |
|
|
2021
Q1 | $4.1M | Sell |
86,581
-23,497
| -21% | -$1.4M | ﹤0.01% | 1691 |
|
|
2020
Q4 | $6.72M | Sell |
110,078
-4,593
| -4% | -$271K | ﹤0.01% | 1352 |
|
|
2020
Q3 | $5.36M | Sell |
114,671
-42,200
| -27% | -$2.08M | ﹤0.01% | 1353 |
|
|
2020
Q2 | $7.96M | Sell |
156,871
-18,276
| -10% | -$898K | 0.01% | 1086 |
|
|
2020
Q1 | $7.81M | Buy |
175,147
+8,341
| +5% | +$420K | 0.01% | 1147 |
|
|
2019
Q4 | $8.01M | Sell |
166,806
-121,499
| -42% | -$5.16M | ﹤0.01% | 1574 |
|
|
2019
Q3 | $9.75M | Buy |
288,305
+131,140
| +83% | +$5.71M | 0.01% | 1299 |
|
|
2019
Q2 | $7.07M | Buy |
157,165
+98,301
| +167% | +$3.88M | ﹤0.01% | 1572 |
|
|
2019
Q1 | $2.22M | Buy |
58,864
+20,362
| +53% | +$684K | ﹤0.01% | 2460 |
|
|
2018
Q4 | $1.32M | Sell |
38,502
-11,930
| -24% | -$429K | ﹤0.01% | 2826 |
|
|
2018
Q3 | $2.37M | Buy |
50,432
+6,570
| +15% | +$272K | ﹤0.01% | 2683 |
|
|
2018
Q2 | $1.48M | Sell |
43,862
-200,337
| -82% | -$6.25M | ﹤0.01% | 2856 |
|
|
2018
Q1 | $6.61M | Buy |
244,199
+213,145
| +686% | +$5.4M | 0.01% | 1429 |
|
|
2017
Q4 | $518K | Sell |
31,054
-26
| -0.1% | -$440 | ﹤0.01% | 3791 |
|
|
2017
Q3 | $622K | Sell |
31,080
-59,881
| -66% | -$1.17M | ﹤0.01% | 3411 |
|
|
2017
Q2 | $1.67M | Buy |
90,961
+13,753
| +18% | +$185K | ﹤0.01% | 2408 |
|
|
2017
Q1 | $759K | Buy |
77,208
+52,869
| +217% | +$640K | ﹤0.01% | 2987 |
|
|
2016
Q4 | $265K | Sell |
24,339
-64,817
| -73% | -$680K | ﹤0.01% | 3973 |
|
|
2016
Q3 | $1.25M | Buy |
89,156
+74,352
| +502% | +$604K | ﹤0.01% | 2422 |
|
|
2016
Q2 | $103K | Buy |
14,804
+238
| +2% | +$1.75K | ﹤0.01% | 4381 |
|
|
2016
Q1 | $87K | Sell |
14,566
-417,716
| -97% | -$7.25M | ﹤0.01% | 4446 |
|
|
2015
Q4 | $13.8M | Buy |
432,282
+83,130
| +24% | +$2.45M | 0.02% | 735 |
|
|
2015
Q3 | $9.08M | Buy |
349,152
+296,127
| +558% | +$12.7M | 0.01% | 996 |
|
|
2015
Q2 | $2.54M | Buy |
53,025
+50,264
| +1,820% | +$2.93M | ﹤0.01% | 2029 |
|
|
2015
Q1 | $166K | Sell |
2,761
-152
| -5% | -$9.27K | ﹤0.01% | 4489 |
|
|
2014
Q4 | $148K | Buy |
2,913
+451
| +18% | +$19.9K | ﹤0.01% | 4877 |
|
|
2014
Q3 | $108K | Sell |
2,462
-3,960
| -62% | -$124K | ﹤0.01% | 5264 |
|
|
2014
Q2 | $167K | Buy |
6,422
+2,077
| +48% | +$44.5K | ﹤0.01% | 4977 |
|
|
2014
Q1 | $112K | Buy |
4,345
+4,110
| +1,749% | +$110K | ﹤0.01% | 5345 |
|
|
2013
Q4 | $3K | Sell |
235
-307
| -57% | -$5.4K | ﹤0.01% | 7282 |
|
|
2013
Q3 | $11K | Buy |
+542
| New | +$9.42K | ﹤0.01% | 6759 |
|
Other funds holding PTCT
RI
JT
Barclays's PTCT Position: Q2 2026 in Review
Barclays increased its PTC Therapeutics (PTCT) stake by 10% in Q2 2026, buying an estimated $382K and bringing the position to 58,370 shares worth $4.76M. The position accounts for ﹤0.01% of the portfolio, ranked #1875.
Barclays first reported a position in PTCT in Q3 2013 and has held it in 52 quarters since. The position peaked at $16.7M in Q4 2025. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.
- Barclays held 58,370 shares of PTC Therapeutics worth $4.76M as of Q2 2026.
- Barclays bought 5,291 PTC Therapeutics shares in Q2 2026, an estimated $382K.
- PTC Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #1875 holding.
- Barclays first reported a position in PTC Therapeutics in Q3 2013 and has held it in 52 quarters since.
- Barclays's PTC Therapeutics position peaked at $16.7M in Q4 2025.
- 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.
Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.